Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 5 Issue 12, December 2006

In This Issue

Top of page ⤴

Editorial

Top of page ⤴

News and Analysis

Top of page ⤴

News in Brief

Top of page ⤴

Patent Watch

Top of page ⤴

News and Analysis

Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Leonard Saltz
    • Chris Easley
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

  • For the past decade, the number of molecular targets for approved drugs has been debated. In this article and the accompanying poster, Overington and colleagues provide a comprehensive survey of current drug targets and a wealth of associated information on the characteristics of target families and the drugs that modulate them.

    • John P. Overington
    • Bissan Al-Lazikani
    • Andrew L. Hopkins
    Opinion
Top of page ⤴

Review Article

  • The Wnt signalling pathway has a central role in tissue development and tissue maintenance, but is frequently dysregulated in several types of cancer, particularly those of the digestive tract. Here, Barker and Clevers examine the recent progress in the development of Wnt inhibitors as anticancer drugs.

    • Nick Barker
    • Hans Clevers
    Review Article
  • There are currently serious concerns about the control measures that should be taken if a pandemic of influenza A were to strike. De Clercq discusses the therapeutic potential of agents that have been shown to be active against influenza A viruses, and describes emerging strategies for targeting these viruses.

    • Erik De Clercq
    Review Article
  • The hedgehog signalling pathway is abnormally activated in most basal cell carcinomas, in one-third or more medulloblastomas, and has been implicated in several other types of cancer. Rubin and de Sauvage discuss the therapeutic opportunities presented by recent insights into this pathway, and the compounds currently in development.

    • Lee L. Rubin
    • Frederic J. de Sauvage
    Review Article
  • Recent developments in the understanding of the mechanisms of cardiac arrhythmias have opened up unprecedented opportunities for drug development. Here, Nattel and Carlsson review emerging findings in the development of new types of anti-arrhythmic compounds targeting two particularly important cardiac arrhythmias: atrial fibrillation and ventricular fibrillation.

    • Stanley Nattel
    • Leif Carlsson
    Review Article
Top of page ⤴

Careers and Recruitment

Top of page ⤴

Focus

  • For the past decade, the number of molecular targets for approved drugs has been debated. However, to develop and apply predictive methods to assess the future potential for therapeutic exploitation, the number, characteristics and biological diversity of these targets needs to be established. Here, we provide a comprehensive survey of current drug targets and drugs that modulate them.

    Focus
Top of page ⤴

Search

Quick links